Tumor infiltrating lymphocytes (TILs) for solid tumors

TILs are autologous tumor infiltrating lymphocyte (TIL)-based cell therapy indicated for the treatment of solid tumors. The cells are further stimulated in the laboratory, and their numbers increase before injection. The TILs are then injected back into patients (adoptive transfer) after the patients have undergone preparatory chemotherapy to improve TILs survival. TILs injection is accompanied by the administration of cytokines, such as interleukin-2 and filgastrim. The treatment results in rapid in vivo growth of tumor-specific clonal populations of T cells and resulted in the regression of metastatic tumors.